Breaking the high -end antibiotic market for decades of predicament for the domestic "super anti -anti -anti -anti -resistance" accumulation

In the "low -key" market of antibiotics, there is a saying that before the invention of antibiotics, human medicine was a joke.

In less than a century, antibiotics have increased the average life expectancy of human beings at least 10 years. But on the other side of the coin, the problem of resistance brought by large -scale use is becoming more and more prominent. The WHO warned that by 2050, the number of antibacterial resistance will exceed cancer, reaching 10 million people.

In the entanglement of "angels" and "devil", bacteria are "exercise" more and more powerful, but humans have not been so fast for human development of new resistant bacteria antibiotics. The global market has not appeared in a stronger super antibiotics for a while.

On July 18, Shanghai League Science and Pharmaceutical Co., Ltd. announced that it will be publicly launched on the Science and Technology Board for the first time, which is expected to become China's "super -resistant first share". The company's core products, high -end antibiotics, were approved for listing in China in June 2021, and were included in national medical insurance at the end of the year. This is a variety beyond the existing top antibiotics, and it is also my country's first super antibiotic independently developed.

In the battle against super bacteria, the world finally had new "weapons".

Under the "Restriction Order", the rise of the high -end antibiotics market

For a period of time, Chinese antibiotics were seriously abused.

At the two sessions of 2011, the academician of the Chinese Academy of Engineering Zhong Nanshan bluntly stated: Even if it was treating a general cold and fever, 80%of them were using antibiotics, which was completely unnecessary.

Under the inertia of antibiotics "cure all diseases", the problem of drug resistance is becoming increasingly serious. Especially after the global "super bacteria" incident in 2010, the former Ministry of Health began to attach importance to this phenomenon. In 2012, the "Administrative Measures for the Clinical Application of Antibacterial Drugs", known as the most stringent "restriction order", was introduced, and the spearhead pointed directly at ordinary antibiotic abuse.

Since then, the domestic antibiotics market has been regulated. However, with the improvement of domestic treatment technology and the increase in drugs, high -end antibiotics that are used for postoperative anti -and infected infections have a significant growth trend.

"Restrictions" only restrict the abuse of ordinary antibiotics. The resistance to resistance derived from antibiotics must be resolved by high -end antibiotics. At present, the main clinical resistance is multiple types of drug -resistant Grand -resistant bacteria and multiple drug -resistant Gram -resistant bacteria.

From 2016 to 2020, the total number of anti -drug -resistant bacteria drugs in China increased from 7.871 million days to 11.241 million days, and the market size of related drugs reached 4.1 billion yuan. It is expected that by 2030, this number will reach 10.8 billion yuan.

Data Source: Figure input diagram of the prospectus of the alliance Science and Pharmaceutical Industry

The current ultra -antibiotic market is mainly the two old medicines that were born in the last century. There are not many methods to deal with drug -resistant bacteria in China, so these two medicines add up to the market with more than 70%of super antibiotics.

From 2016 to 2020, Vancin's sales in China remained stable, from 1.526 billion yuan to 1.604 billion yuan; sales of Lenitidaids increased from 688 million yuan to 1.486 billion yuan.

Source: League Science and Pharmaceutical Prospectus instructions

Vancin and Lenitidaids have certain defects in toxicity and antibacterial effects, but they are not available clinically. Therefore, the hospital has to be very cautious when applying these two super antibiotics. Not only China, but in fact, the world is facing similar problems.

In recent years, multinational companies such as Novartis, Asley, and Sanofi have announced the termination of super antibiotic research and development. High technology is a great factor.

The market urgently needs a stronger high -end antibiotics to more effectively resist the resistance of bacteria.

The new generation of super -resistant "Kangozazzra": Rare R & D highland of competitors

In June 2021, Kangozoraz, which was treated with the treatment of multiple drug -resistant germs, was approved to be listed in China. In the year of the listing, Kangntozide successfully entered the national medical insurance.

According to data on the prospectus of the alliance, in the first quarter of 2022, the sales of Kangozizozozoid reached 10.687 million yuan, exceeding the whole year of 2021.

New blood has appeared in the high -end antibiotic market, which has not appeared in the world for many years.

Fighting from multiple drug -resistant germs, villainopatramone is the highest proportion of varieties. Cumfolzozrazolid and Lenitoraid are all villainopatramone drugs. According to the Fifrrishalvan report, between 2020 and 2030, the market of Chinese ovilizoline antibacterial drugs is expected to increase from 1.5 billion yuan to 6 billion yuan to treat the antibacterial drug market for multiple drug-resistant germs infection. It will be more than 50%.

As a new generation of high -end hyperbacteroline antibacterials, Ketozozoz is a chemical structure on the basis of rhizolid. The research is very deep, so it can find a small breakthrough in the chemical structure and improve it. The prospectus of the alliance medicine shows that the effect of Kangyrazide has better effect, and at the same time reduces the side effects of rhizolid, and has higher safety.

There are many applications in clinical anti -drug infections. More than 10 departments such as hematology, intensive medical department, and neurosurgery may use super antibiotics. In the rehabilitation stage after large surgery and tumor chemotherapy, super antibiotics can control the infection when the human body is the weakest to ensure the recovery of the disease.

At present, Kangozozoz is now a first -line medication for anti -drug infection of medical insurance, while Lenitizaid is a second line, and must be used after the treatment of vanomycin. In other words, on the long journey of human beings to overcome anti -drug -resistant bacteria, Lianke Pharmaceutical has run at the forefront, and there are almost no competitors in the short term. In addition, Lianke Pharmaceuticals also developed a "upgraded version" injection MRX-4 on the basis of Kangzozoraz. It has now advanced to the global phase III clinical stage. The indications have also expanded to diabetic foot infections, which can better solve the solution No clinical needs are met in this field.

Some industry data predicts that in the future, the total sales of the two products of oral dosage-type Kangntozozamidozozozoraz and its injection type MRX-4 are expected to exceed the peak sales of $ 1.4 billion in Rinzolid.

Domestic high -end antibiotics, moving towards the global market

Different from many innovative pharmaceutical companies, the League Science and Pharmaceutical Industry has chosen a completely self -developed and international innovation route since its establishment. The company's founding team was initially founded in the United States and was very familiar with the needs and pattern of the American antibiotic market. At present, the company's indications in the company are clinically clinically clinically clinically clinically clinically clinic, and R & D centers have been established in China and the United States.

Photo: Prospects for the League Science and Pharmaceutical Industry

The United States is a big country for super antibiotic applications, but it also lacks more powerful drugs. At present, antibiotics of antibiotics in the United States are almost all old medicines, but in 2020, the total number of days of super antibiotics in the United States has reached 1750 Wan Tian is 1.5 times domestic.

Over the past five years, the United States has also sold antibacterial drugs during the patent period of more than 300 million US dollars.

The global phase III clinical of Kangzozoraz and injection-type MRX-4 of the Kyoto Pharmaceuticals has been in progress. The company plans to achieve approval in the US market two years later. At the same time, the MRX-8 product of the Drug-resistant Gram-resistant Gram-resistant Gram-resistant Gram-Pharmaceutical Industry has also entered the clinical stage of phase I in the United States. It has significant effects in reducing renal toxicity and neurotoxicity. It is expected to break long-term negative resistance. Puppet bacteria without medicine.

In addition to super antibiotics, alliances are also actively developing other varieties, such as using antibiotic technology to develop two nephrotic drugs, and using their own advantages to develop popular ADC drugs, small molecules and other popular fields such as small molecules and other popular fields Essence

There will not be a return to choose the difficulty of going; but once it goes through, the pursuit and exploration of the past few decades is worth it.

#Antibiotics ## 唑 唑 ## 盟 盟#

- END -